Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi's blockbuster Dupixent drug clears major trial
10:43am, Thursday, 23'rd Mar 2023
French pharma multinational Sanofi's Dupixent drug has achieved impressive results in a late-stage trial to treat chronic obstructive pulmonary disease (COPD), aka ‘smoker's lung'. Developed jointly
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
09:03am, Thursday, 23'rd Mar 2023
Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
07:42am, Tuesday, 21'st Mar 2023
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
ACER's Stock Down on Failure of Phase II Study, Cash Updates
01:46pm, Monday, 20'th Mar 2023
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
11:30am, Friday, 17'th Mar 2023
Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.
Sanofi becomes latest to cut insulin prices, joins Novo Nordisk, Eli Lilly
10:25am, Friday, 17'th Mar 2023
Yahoo Finance's Anjalee Khemlani joins the Live show to report that Sanofi has become the latest major drug company to slash insulin prices, capping the cost at $35.
Sanofi Cuts Insulin Prices Up To 78%—Following Eli Lilly And Novo Nordisk
05:45pm, Thursday, 16'th Mar 2023
The French company will cap the monthly cost of insulin at $35, after Novo Nordisk and Eli Lilly also announced major price cuts earlier this month.
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk
04:45pm, Thursday, 16'th Mar 2023
The French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Sanofi to cap price of Lantus insulin at $35
04:24pm, Thursday, 16'th Mar 2023
Sanofi SNY FR:SAN said Thursday that it will cut the U.S. list price of Lantus by 78%, and it will also cap out-of-pocket costs at $35 for the same insulin for people with commercial health insurance,
2 Top Biotech Stocks to Buy Right Now
09:30am, Wednesday, 15'th Mar 2023
Sanofi and Amgen both have the two most important characteristics that investors should seek from pharmaceutical companies. Sanofi stock is where growth and value intersect.
This biopharma stock jumped over 250% on Monday: what happened?
08:22pm, Monday, 13'th Mar 2023
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.
Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions
05:34pm, Monday, 13'th Mar 2023
Last week ended on a hectic note
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
10:15am, Monday, 13'th Mar 2023
French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
09:17am, Monday, 13'th Mar 2023
Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
06:43am, Monday, 13'th Mar 2023
Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.
